Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT-122 in NSCLC Cachexia
NCT00527319Phase 2Completed
- Sponsor
- Vicus Therapeutics
- Start
- Jan 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of propranolol, etodolac in cachexia, sponsored by Vicus Therapeutics. Started Jan 2007; status: completed.
02
Drugs
propranololetodolac
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT00527319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00527319.